Inventure leads €2m Blueprint Genetics funding round

Co-investment was provided by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation, bringing the total amount raised by Blueprint to around €2.96m.

The company will use the fresh capital to support its international expansion, which will kick off with the opening of an office in the US.

Company
The Helsinki-based company provides a genetic diagnostics platform through its Next-Generation Sequencing technology, which is used to diagnose genetic diseases before they manifest in order to aid treatment and preventative care.

Founded in 2012, Blueprint's first product helps diagnose cardiovascular disorders. The company has clients including more than 60 hospitals in 10 countries.

People
Tommi Lehtonen is the CEO of Blueprint. Ekaterina Gianelli is a director with Inventure.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Expansion
• Healthcare
• Tekes
• Finland